Patent ID: 9579364
Date: 2017-02-28
CPC Classifications: A61K,A61P

Claim:
1. A method for treating a subject with benign prostatic hyperplasia (BPH) disease, the method comprising administering a therapeutically effective amount of an inhibitor of IGF-I activity to a subject with BPH, wherein the inhibitor of IGF-I activity is synthetic somatostatin 14, a somatostatin analog, or a small molecule IGF-I receptor kinase specific inhibitor and the therapeutically effective amount of the inhibitor of IGF-I activity is administered to reduce the amount of prostatic hyperplastic tissue in the subject and thereby alleviate adverse symptoms of BPH in the subject, wherein the adverse symptoms comprise irritative or obstructive voiding pattern, urinary retention, and/or frequent urination with an increased residual urine volume, thereby treating the subject with BPH.